Dylan Dupuis
Stock Analyst at Roth MKM
(2.64)
# 1,988
Out of 5,154 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $28 | $1.88 | +1,389.36% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $6.13 | +79.45% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $42.82 | -46.29% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $32.98 | -2.97% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $1.88
Upside: +1,389.36%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $6.13
Upside: +79.45%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $42.82
Upside: -46.29%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $32.98
Upside: -2.97%